

APPLICANT(S): YEDGAR, Saul et al.
SERIAL NO.: 10/627,981
FILED: July 28, 2003
Page 2

AMENDMENTS TO THE CLAIMS

Please amend the claims to read as follows:

1. *(Currently amended)* A method of treating a subject suffering from sepsis, comprising the steps of administering to said subject an effective amount of a lipid or phospholipid moiety bonded to a glycosaminoglycan, via an amide or ester linkage, thereby treating the subject suffering from sepsis.
2. *(Withdrawn)* The method of claim 1, wherein ^{*the glycosaminoglycan is*} ~~said physiologically acceptable monomer is a salicylate, salicylic acid, aspirin, a monosaccharide, lactobionic acid, glucuronic acid, maltose, amino acid, glycine, carboxylic acid, acetic acid, butyric acid, dicarboxylic acid, glutaric acid, succinic acid, fatty acid, dodecanoic acid, didodecanoic acid, bile acid, cholic acid, cholesterylhemisuccinate; or wherein the physiologically acceptable dimer or oligomer is a dipeptide, a disaccharide, a trisaccharide, an oligosaccharide, an oligopeptide, or a di- or trisaccharide monomer unit of glycosaminoglycans, hyaluronic acid, heparin, heparan sulfate, keratin, keratan sulfate, chondroitin, chondroitin sulfate, chondroitin-4-sulfate, chondroitin-6-sulfate, dermatin, dermatan sulfate, ^{*or a derivative thereof.*} dextran, polygeline, alginate, hydroxyethyl starch, ethylene glycol, or carboxylated ethylene glycol; or wherein the physiologically acceptable polymer is a glycosaminoglycan, hyaluronic acid, heparin, heparan sulfate, chondroitin, chondroitin sulfate, keratin, keratan sulfate, dermatin, dermatan sulfate, carboxymethylcellulose, dextran, polygeline, alginate, hydroxyethyl starch, polyethylene glycol or polycarboxylated polyethylene glycol.~~
3. *(Previously presented)* The method of claim 1, wherein said glycosaminoglycan is hyaluronic acid.
4. *(Previously presented)* The method of claim 1, wherein said glycosaminoglycan is chondroitin sulfate.
5. *(Withdrawn)* The method of claim 1, wherein said lipid or phospholipid moiety is phosphatidic acid, an acyl glycerol, monoacylglycerol, diacylglycerol, triacylglycerol, sphingosine, sphingomyelin, ceramide, phosphatidylethanolamine, phosphatidylserine,

APPLICANT(S): YEDGAR, Saul et al.
SERIAL NO.: 10/627,981
FILED: July 28, 2003
Page 3

phosphatidylcholine, phosphatidylinositol, phosphatidylglycerol, or an ether or alkyl phospholipid derivative thereof.

6. *(Original)* The method of claim 1, wherein said phospholipid moiety is phosphatidylethanolamine.

7. *(Previously presented)* The method of claim 1, wherein said lipid or phospholipid moiety bonded to a glycosaminoglycan is administered as part of a pharmaceutical composition.

8. -18. *Cancelled.*

⁸ 19. *(Previously presented)* The method of claim 6, where said phosphatidylethanolamine moiety is dimyristoyl phosphatidylethanolamine.

⁹ 20. *(Previously presented)* The method of claim 1, wherein said phospholipid moiety is dipalmitoyl phosphatidylethanolamine and said glycosaminoglycan is hyaluronic acid.

¹⁰ 21. *(Previously presented)* The method of claim 1, wherein said phospholipid moiety is dimyristoyl phosphatidylethanolamine and said glycosaminoglycan is hyaluronic acid.

¹¹ 22. *(Previously presented)* The method of claim 1, wherein said phospholipid moiety is dipalmitoyl phosphatidylethanolamine and said glycosaminoglycan is chondroitin sulfate.

¹² 23. *(New)* The method of claim 6, where said phosphatidylethanolamine moiety is dipalmitoyl phosphatidylethanolamine.

¹³ 24. *(New)* The method of claim 1, wherein said glycosaminoglycan is heparin.

¹⁴ 25. *(New)* The method of claim 1, wherein said phospholipid moiety is dipalmitoyl phosphatidylethanolamine and said glycosaminoglycan is heparin.